Redox dysregulation, neurodevelopment, and schizophrenia

Current Opinion in Neurobiology

Volumn 19, Issue 2, 2009, Pages 220-230

  Do, Kim Q ^a   Cabungcal, Jan H ^a   Frank, Anita ^a   Steullet, Pascal ^a   Cuenod, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCYSTEINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PLACEBO;

ADD ON THERAPY; AKATHISIA; BRAIN DEVELOPMENT; CINGULATE GYRUS; DOPAMINE METABOLISM; ENVIRONMENTAL FACTOR; GABAERGIC SYSTEM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLUTATHIONE METABOLISM; HIPPOCAMPUS; HUMAN; LEARNING; LONG TERM POTENTIATION; MENTAL STRESS; MISMATCH NEGATIVITY; MYELINATION; NERVE CELL NETWORK; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OLFACTORY DISCRIMINATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; WORKING MEMORY;

ANIMALS; BRAIN; GLUTATHIONE; HUMANS; MODELS, NEUROLOGICAL; OXIDATION-REDUCTION; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 67650932879     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conb.2009.05.001     Document Type: Review

References (81)

1. Tandon R., Keshavan M.S., and Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102 (2008) 1-18
2. Van O.J., Rutten B.P., and Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 34 (2008) 1066-1082. This is an excellent review on the gene-environment interactions in the etiology of schizophrenia, with an emphasis on major environmental factors.
3. Lewis D.A., and Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25 (2002) 409-432
4. Rapoport J.L., Addington A.M., Frangou S., and Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10 (2005) 434-449
5. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39 (2007) 44-84. This is an excellent review on reactive oxygen species (ROS) and reactive nitrogen species (RNS, e.g. nitric oxide, NO{radical dot}) and their dual role as both deleterious and beneficial species. ROS and RNS are normally generated by tightly regulated enzymes, such as NO synthase (NOS) and NAD(P)H oxidase isoforms, respectively. Overproduction of ROS results in oxidative stress, a deleterious process and important mediator of damage to cell structures, including lipids and membranes, proteins, and DNA. At low/moderate concentrations, beneficial effects of ROS/RNS involve physiological roles in cellular responses to noxia, as for example in defense against infectious agents, in the function of a number of cellular signaling pathways, and the induction of a mitogenic response. Various ROS-mediated actions in fact protect cells against ROS-induced oxidative stress and re-establish or maintain 'redox balance' termed also 'redox homeostasis'.
6. Jones D.P. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 295 (2008) C849-C868. Besides free radical-induced macromolecular damage that has been studied extensively as a mechanism of oxidative stress, this timely review focuses on the involvement of redox dysregulation that can occur without free radical generation. Oxidative stress can also occur as a consequence of the disruption of thiol redox circuits, which normally function in cell signaling and physiological regulation. The redox states of thiol systems are sensitive to two electron oxidants and controlled by the thioredoxins (Trx), GSH, and cysteine. Trx and GSH systems are maintained under stable, but nonequilibrium conditions, because of the continuous oxidation of cell thiols at a rate of about 0.5% of the total thiol pool per minute. Redox-sensitive thiols are critical for signal transduction (e.g. H-Ras and PTP-1B), transcription factor binding to DNA (e.g. Nrf-2, nuclear factor-κB), receptor activation (e.g. NMDA receptor), and other processes. Nonradical oxidants, including peroxides, quinones are generated enzymatically from both endogenous (e.g. dopamine) and exogenous precursors and do not require free radicals as intermediates to oxidize or modify these thiols and disrupt function.
7. Shi Z.Z., Osei-Frimpong J., Kala G., Kala S.V., Barrios R.J., Habib G.M., Lukin D.J., Danney C.M., Matzuk M.M., and Lieberman M.W. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc Natl Acad Sci U S A 97 (2000) 5101-5106
8. Lipton S.A., Choi Y.B., Takahashi H., Zhang D., Li W., Godzik A., and Bankston L.A. Cysteine regulation of protein function - as exemplified by NMDA-receptor modulation. Trends Neurosci 25 (2002) 474-480
9. Lu S.C. Regulation of glutathione synthesis. Mol Aspects Med 30 (2009) 42-59. This is an extensive review on the biological functions of GSH, its synthesis and metabolism and on transcription factors controlling its regulation. This is a brief survey of its perturbation in various pathologies.
10. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58 (2002) 1-10
11. Yao J.K., Leonard S., and Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 22 (2006) 83-93
12. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., and Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6 (2001) 66-73
13. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9 (2004) 684-697 643
14. Do K.Q., Bovet P., Cabungcal J.H., Conus P., Gysin R., Lavoie S., Steullet P., and Cuenod M. Redox dysregulation in schizophrenia: genetic susceptibility and pathophysiological mechanisms. In: Lajtha A. (Ed). Handbook of Neurochemistry and Molecular Neurobiology vol 27 (2009), Springer, New York. This is a review covering in detail some topics of the present paper.
15. Tosic M., Ott J., Barral S., Bovet P., Deppen P., Gheorghita F., Matthey M.L., Parnas J., Preisig M., Saraga M., et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 79 (2006) 586-592
16. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., Deppen P., Preisig M., Ruiz V., Steullet P., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A 104 (2007) 16621-16626. This paper presents the trinucleotid polymorphism associated with schizophrenia in the gene of the GSH synthesizing enzyme and its functional consequences in fibroblasts challenged by an oxidative stress, revealing dysregulation of the redox homeostasis.
17. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., and Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12 (2000) 3721-3728
18. Matsuzawa D., Obata T., Shirayama Y., Nonaka H., Kanazawa Y., Yoshitome E., Takanashi J., Matsuda T., Shimizu E., Ikehira H., et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE 3 (2008) e1944. GSH levels measured by MRS in posterior medial frontal cortex of 20 schizophrenia patients were negatively correlated with negative symptoms. There was no significant changes in GSH levels when compared with normal controls, probably because of genotypes heterogeneity.
19. Kempf L., Nicodemus K.K., Kolachana B., Vakkalanka R., Verchinski B.A., Egan M.F., Straub R.E., Mattay V.A., Callicott J.H., Weinberger D.R., and Meyer-Lindenberg A. Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet 4 (2008) e1000252
20. Phang J.M., Donald S.P., Pandhare J., and Liu Y. The metabolism of proline, a stress substrate, modulates carcinogenic pathways. Amino Acids 35 (2008) 681-690
21. Akbarian S., and Huang H.S. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry 65 (2009) 198-203
22. Deth R., Muratore C., Benzecry J., Power-Charnitsky V.A., and Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 29 (2008) 190-201
23. Brown A.S., Bottiglieri T., Schaefer C.A., Quesenberry Jr. C.P., Liu L., Bresnahan M., and Susser E.S. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 64 (2007) 31-39
24. Mittal V.A., Ellman L.M., and Cannon T.D. Gene-environment interaction and covariation in schizophrenia: the role of obstetric complications. Schizophr Bull 34 (2008) 1083-1094
25. Brown A.S., and Susser E.S. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr Bull 34 (2008) 1054-1063
26. Garcia-Bueno B., Madrigal J.L., Lizasoain I., Moro M.A., Lorenzo P., and Leza J.C. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 57 (2005) 885-894
27. Paintlia M.K., Paintlia A.S., Khan M., Singh I., and Singh A.K. Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures. J Neurochem 105 (2008) 956-970. Prenatal inflammation (via LPS) induces selective depletion of developing oligodendrocytes and hypomyelination via a decrease in GSH, increase in ROS, and dysfunction of peroxisomes. N-Acetylcysteine prevents LPS-induced redox dysregulation and attenuates hypomyelination via a PPAR-α-dependent mechanism.
28. Meyer U., Nyffeler M., Yee B.K., Knuesel I., and Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 22 (2008) 469-486
29. Meyer U., Nyffeler M., Engler A., Urwyler A., Schedlowski M., Knuesel I., Yee B.K., and Feldon J. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 26 (2006) 4752-4762
30. Lante F., Meunier J., Guiramand J., Maurice T., Cavalier M., de Jesus Ferreira M.C., Aimar R., Cohen-Solal C., Vignes M., and Barbanel G. Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain. Free Radic Biol Med 42 (2007) 1231-1245
31. Li Z., Dong T., Proschel C., and Noble M. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol 5 (2007) e35. In previous study [64], the authors showed that the redox status induced by various growth factors determine the fate of oligodendrocyte precursors, with oxidizing factors favoring differentiation while reducing status promote precursor proliferation. Here they show that exposure of mercury and other pro-oxidant toxins lead to more oxidized conditions in oligodendrocyte precursors and suppress their division via the downregulation of PDGFR-α. This downregulation is due to enhanced degradation of PDGFR-α through activation of Fyn and c-CBl. The antioxidant N-acetylcysteine prevents this deleterious effect of the pro-oxidant toxins.
32. Chakraborti A., Gulati K., Banerjee B.D., and Ray A. Possible involvement of free radicals in the differential neurobehavioral responses to stress in male and female rats. Behav Brain Res 179 (2007) 321-325
33. Lewis D.A., and Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28 (2000) 325-334
34. Steullet P., Lavoie S., Kraftsik R., Guidi R., Gysin R., Cuenod M., and Do K.Q. A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons. Free Radic Biol Med 44 (2008) 1042-1054. This paper describes a mechanism by which dopamine signaling can be affected in conditions of impaired GSH synthesis. In cultured cortical neurons, a GSH deficit changes the dopamine modulation of NMDA-mediated calcium responses, from enhanced responses in control neurons to decreased responses in low GSH neurons. This is due to a change in dopamine modulation of L-type calcium channels which is dependent on redox-sensitive ryanodine receptors (RyRs), whose function is enhanced in low GSH neurons. Blocking D2R receptors prevents the alteration of dopamine modulation induced by a GSH deficit. Data suggest that enhanced RyRs in low GSH neurons strengthens intracellular calcium-dependent pathways following activation of D2-type receptors and causes a decrease in function of L-type channels.
35. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
36. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
37. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26 (2006) 365-384
38. Kohr G., Eckardt S., Luddens H., Monyer H., and Seeburg P.H. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 12 (1994) 1031-1040
39. Steullet P., Neijt H.C., Cuenod M., and Do K.Q. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 137 (2006) 807-819
40. Papadia S., Soriano F.X., Leveille F., Martel M.A., Dakin K.A., Hansen H.H., Kaindl A., Sifringer M., Fowler J., Stefovska V., et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11 (2008) 476-487. This is an elegant piece of work that has identified a new NMDAR-mediated, synaptic (but not extrasynaptic) activity-dependent web of coordinated transcriptional changes that lead to enhanced neuronal antioxidant defenses, particularly relevant in diseases associated with oxidative damage. Thus the toxicity of NMDAR antagonists such as MK-801 on neonatal neurons may be due from their blockade of synaptic activity, and therefore the antioxidant pathways.
41. Zuo D.Y., Wu Y.L., Yao W.X., Cao Y., Wu C.F., and Tanaka M. Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol Biochem Behav 86 (2007) 1-7
42. Benes F.M., and Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25 (2001) 1-27
43. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6 (2005) 312-324
44. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., and Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31 (2008) 234-242
45. Braun I., Genius J., Grunze H., Bender A., Moller H.J., and Rujescu D. Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res 97 (2007) 254-263
46. Abekawa T., Ito K., Nakagawa S., and Koyama T. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats. Psychopharmacology (Berl) 192 (2007) 303-316
47. Cabungcal J.H., Nicolas D., Kraftsik R., Cuenod M., Do K.Q., and Hornung J.P. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis 22 (2006) 624-637. This study is the first to show that a low glutathione during early brain development leads to a specific impairment of parvalbumin-immunoreactive (fast-spiking GABAergic interneuron) profiles in anterior cingulate cortex of a rat.
48. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., and Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 26 (2006) 1604-1615. PV interneurons have a five times higher NR2A/NR2B ratio than pyramidal neurons and NR2A-selective, but not NR2B-selective antagonist reduces PV-IR: this indicates a role of NR2A-containing NMDAR in the maintenance of functional fast-spiking PV interneurons.
49. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., and Dugan L.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318 (2007) 1645-1647. Ketamine-induced decrease in GAD67 and PV expression is due to the production of superoxide via NADPH-oxidase activity. This deleterious effect on fast-spiking PV interneurons is prevented by apocinin, an inhibitor of NADPH-oxidase, or a SOD-mimetic compound.
50. Behrens M.M., Ali S.S., and Dugan L.L. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 28 (2008) 13957-13966. Neuronal production of interleukin-6 is necessary and sufficient for ketamine-mediated activation of NADPH-oxidase leading to dysfunction of fast-spiking PV interneurons.
51. Cowell R.M., Blake K.R., and Russell J.W. Localization of the transcriptional coactivator PGC-1alpha to GABAergic neurons during maturation of the rat brain. J Comp Neurol 502 (2007) 1-18
52. Grima G., Benz B., Parpura V., Cuenod M., and Do K.Q. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 62 (2003) 213-224
53. Spencer K.M., Nestor P.G., Niznikiewicz M.A., Salisbury D.F., Shenton M.E., and McCarley R.W. Abnormal neural synchrony in schizophrenia. J Neurosci 23 (2003) 7407-7411
54. Uhlhaas P.J., Linden D.E., Singer W., Haenschel C., Lindner M., Maurer K., and Rodriguez E. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J Neurosci 26 (2006) 8168-8175
55. Tallon-Baudry C., Bertrand O., Delpuech C., and Permier J. Oscillatory gamma-band (30-70 Hz) activity induced by a visual search task in humans. J Neurosci 17 (1997) 722-734
56. Uhlhaas P.J., and Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 52 (2006) 155-168
57. Traub R.D., Whittington M.A., Stanford I.M., and Jefferys J.G. A mechanism for generation of long-range synchronous fast oscillations in the cortex. Nature 383 (1996) 621-624
58. Sohal VS, Zhang F, Yizhar O, Deisseroth K: Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009, (online 26 April 2009) doi:10.1038/nature07991 Letter. This elegant study uses a panel of optogenetic technologies to show that parvalbumin interneurons are sufficient and necessary to generate emergent gamma-frequency rythmicity in the cortex in-vivo. In addition, gamma-frequency modulation of excitatory inputs enhances signal transmission in neocortex by reducing circuit noise and amplifying circuit signals.
59. Cabungcal J.H., Preissmann D., Delseth C., Cuenod M., Do K.Q., and Schenk F. Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. Neurobiol Dis 26 (2007) 634-645
60. Castagne V., Rougemont M., Cuenod M., and Do K.Q. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 15 (2004) 93-105
61. Castagne V., Cuenod M., and Do K.Q. An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience 123 (2004) 821-834
62. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., Starkey M., Webster M.J., Yolken R.H., and Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362 (2003) 798-805
63. Dracheva S., Davis K.L., Chin B., Woo D.A., Schmeidler J., and Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21 (2006) 531-540
64. Smith J., Ladi E., Mayer-Proschel M., and Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci U S A 97 (2000) 10032-10037
65. Back S.A., Gan X., Li Y., Rosenberg P.A., and Volpe J.J. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J Neurosci 18 (1998) 6241-6253
66. Leisewitz A.V., Urrutia C.R., Martinez G.R., Loyola G., and Bronfman M. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis. J Cell Physiol 217 (2008) 367-376. This study shows respective involvement of PPARs α, β/δ, and γ in oligodendrocyte differentiation and myelin synthesis.
67. Hensch T.K. Critical period plasticity in local cortical circuits. Nat Rev Neurosci 6 (2005) 877-888
68. Morishita H., and Hensch T.K. Critical period revisited: impact on vision. Curr Opin Neurobiol 18 (2008) 101-107. This excellent review and the previous one [70] highlight the impact of critical period on visual acuity and the involvement of PV GABAergic interneurons. This critical period can be manipulated in animal models by resetting excitatory-inhibitory balance or removal of molecular 'brakes' on structural plasticity.
69. McGee A.W., Yang Y., Fischer Q.S., Daw N.W., and Strittmatter S.M. Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 309 (2005) 2222-2226
70. Maya Vetencourt J.F., Sale A., Viegi A., Baroncelli L., De P.R., O'Leary O.F., Castren E., and Maffei L. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 320 (2008) 385-388
71. Zafir A., and Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol 572 (2007) 23-31
72. Pizzorusso T., Medini P., Landi S., Baldini S., Berardi N., and Maffei L. Structural and functional recovery from early monocular deprivation in adult rats. Proc Natl Acad Sci U S A 103 (2006) 8517-8522
73. Butt S.J., Fuccillo M., Nery S., Noctor S., Kriegstein A., Corbin J.G., and Fishell G. The temporal and spatial origins of cortical interneurons predict their physiological subtype. Neuron 48 (2005) 591-604
74. Atkuri K.R., Mantovani J.J., Herzenberg L.A., and Herzenberg L.A. N-Acetylcysteine - a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7 (2007) 355-359
75. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., nderson-Hunt M., Judd F., Katz F., Katz P., et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64 (2008) 361-368
76. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33 (2008) 2187-2199
77. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., and Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57 (2000) 1139-1147
78. Light G.A., and Braff D.L. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry 162 (2005) 1741-1743
79. Jiang M., and Swann J.W. A role for L-type calcium channels in the maturation of parvalbumin-containing hippocampal interneurons. Neuroscience 135 (2005) 839-850
80. Porter L.L., Rizzo E., and Hornung J.P. Dopamine affects parvalbumin expression during cortical development in vitro. J Neurosci 19 (1999) 8990-9003
81. Tseng K.Y., and O'Donnell P. Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cereb Cortex 17 (2007) 1235-1240